MétaCan
Menu
Back to cohort
Record W2519753935

The Modern Merits of South Koreas Biopharmaceutical Industry

2016· article· en· W2519753935 on OpenAlexaboutno aff
Benjamin Rymzo, Nathan Dowden, Regina Salvat, Tom Lee

Bibliographic record

VenueInternational Journal of Drug Development and Research · 2016
Typearticle
Languageen
FieldMedicine
TopicBiotechnology and Related Fields
Canadian institutionsnot available
Fundersnot available
KeywordsGovernment (linguistics)RevenueGeneral partnershipLeverage (statistics)PopulationBusinessEconomic growthEconomicsFinance
DOInot available

Abstract

fetched live from OpenAlex

The overview: In recent years, the South Korean economy has evolved from light goods, to heavy industry, to high tech and biotech. Along the way, the country has built a thoroughly modern legal and regulatory framework, an arguably world class educational infrastructure, and an unusually productive level of public-private partnership activity. How did it get here?: Migrating from a heavy manufacturing economy in the aftermath of the Korean War, South Korea began turning its attention to biopharmaceuticals as an opportunity to leverage the country’s increasing R&D and innovation capabilities, while relieving pressure to meet the healthcare needs and demands of an increasingly mature population. In 1994, the government launched the first national initiative to grow the industry-the “Biotech 2000” plan, investing roughly $20 billion for various biotech-related research initiatives from 1994 to 2000. This was followed by a second government-supported plan dubbed “Bio-Vision 2016,” a ten-year initiative with the goal of making South Korea one of the leading hubs of the biotech industry by 2016. The past decade has witnessed the formation of several key collaborations between South Korean companies and multi-national biopharma firms. Pfizer, AstraZeneca, Bristol-Myers Squibb, Sanofi, Novartis, and Otsuka have all invested heavily in local research and development. What’s the outcome?: As of 2012, South Korea’s top 20 biopharma companies (ranked by 2012 revenue) now total $6,978,110,000. According to the Bloomberg Global Innovation Index, South Korea ranks #1 in the world as the most innovative country in 2015 when considering a variety of metrics such as R&D capacity, productivity, and patent activity. The country’s annual R&D spending totals more than 4 percent of GDP (Source: The World Bank). To support the company’s rapid growth, Samsung announced plans in 2015 to build two more biologics manufacturing plants, at a cost of roughly $1.5 billion, to make the nation one of the largest biologics manufacturers worldwide. Samsung Bioepis is also planning a US IPO in 2016. According to a 2014 IMS report, South Korea’s biopharmaceutical industry is currently ranked fifteenth in the world, and is categorized alongside the United States, the EU5 nations, Japan, and Canada. From these actions, South Korea now ranks among the leading nations on other development indicators such as healthcare, education and R&D expenditure. South Korean life expectancy is now higher than the OECD average at 81 years old.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.838
Threshold uncertainty score0.733

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.059
GPT teacher head0.394
Teacher spread0.334 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designOther design
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueInternational Journal of Drug Development and ResearchSame topicBiotechnology and Related FieldsFrench-language works237,207